Is Enlivex Therapeutics Ltd. (ENLV) a Buy, Sell, or Hold?
Enlivex Therapeutics Ltd.
NASDAQ:ENLV
$5.84 USD
-$0.21 (-3.47%)
- Volume
- 116.92K
- Average Volume
- 31.57K
- Market Capitalization
- $98.3M
- P/E Ratio
- 0.01
- Dividend Yield
- 0.00%
- Price Target
- $15.00
- Year High
- $31.50
- Year Low
- $5.41
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $193.24
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Oren Hershkovitz |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ENLV |
| CUSIP | M4130Y106 |
| CIK | 0001596812 |
| Web | https://www.enlivex.com |
| Phone | 972 8 662 3301 |
| Currency | USD |
| Employees | 34 |
| Country | IL |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 193.24 |
| Quick Ratio | 193.24 |
| Cash Ratio | 0.22 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -3.66 |
| Price / Cash Flow | -8.86 |
| Price / Book | 0.01 |
Price Target and Rating
| Average Stock Price Forecast | $15.00 |
| High Stock Price Forecast | $15.00 |
| Low Stock Price Forecast | $15.00 |
| Forecast Upside/Downside | -61.07% |
| Consensus Rating | Strong Buy |
| Rating Score(0-5) | 5 |
| Research Coverage | 4 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $382.2 |
| Trailing P/E Ratio | 0.01 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $1.24B |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | 248.08% |
| Return on Assets | 53.10% |
Financials Score
| AltmanZ Score | 1.72 |
| Piotroski Score | 3.00 |
| Working Capital | 1.73B |
| Total Assets | 2.33B |
| Ebit | -14.65M |
| Market Cap | 115.47M |
| Total Liabilities | 392.05M |
Poll Results
About Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Stock
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy. ...
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
2026-07-13 13:01:06
Enlivex Ltd. (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-07-13 10:36:03
The heavy selling pressure might have exhausted for Enlivex Ltd. (ENLV) as it is technically in oversold territory now.
2026-07-13 08:00:00
Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™, the Company's clinical-stage immunotherapy, for the treatment of age-related symptomatic knee osteoarthritis (OA) in patients aged 64 and older.
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
2026-07-07 08:00:00
Nes-Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced a 1-for-15 reverse split (the "Reverse Split") of its ordinary shares.
2026-06-24 08:00:00
Nes-Ziona, Israel, June 24, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “ Enlivex ” or the “ Company ” ), a quality longevity company powered by a prediction markets treasury, today announced that its primary treasury asset, the RAIN token, is expected to be listed on the Gate cryptocurrency exchange, effective June 24, 2026 at 10:00 AM UTC. The listing represents a continued expansion of RAIN ' s exchange infrastructure, increasing its accessibility, global reach, and token liquidity. According to Gate, it is one of the world ' s pioneering cryptocurrency exchanges, established in 2013 . Gate is currently serving over 54 million users globally , consistently rank ed among the top three digital asset exchanges worldwide by trading volume and liquidity, and holds the second-largest 24-hour spot trading volume globally. Gate supports spot trading, futures trading, margin trading, and wealth management products for over 4,600 cryptocurrencies.
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
2026-06-22 08:45:00
Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1.
2026-06-15 08:00:00
Nes-Ziona, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the issuance of an Australian patent, numbered 2020340629, titled, “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS”.
2026-06-02 08:00:00
As a Gold Sponsor of the Paris event, Enlivex will host a curated dinner today for leading institutional asset managers, allocators, and digital asset investors Nes-Ziona, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that it is a Gold Sponsor of Proof of Talk 2026, taking place June 2-3, 2026, at the Louvre Palace and Musée des Arts Décoratifs in Paris.
Frequently Asked Questions
-
What is the current Enlivex Therapeutics Ltd. (ENLV) stock price?
-
Enlivex Therapeutics Ltd.(NASDAQ:ENLV) stock price is $5.84 in the last trading session. During the trading session, ENLV stock reached the peak price of $31.5 while $5.405 was the lowest point it dropped to. The percentage change in ENLV stock occurred in the recent session was --3.47% while the dollar amount for the price change in ENLV stock was -$0.21.
-
ENLV's industry and sector of operation?
-
The NASDAQ listed ENLV is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ENLV?
-
Veronique Amor-Baroukh | Senior Director of Operations
Einat Galamidi | Chief Medical Officer
Sigal Arad | Director of Human Resources
Oren Hershkovitz | Chief Executive Officer
Shai Novik | Executive Chairman -
How many employees does ENLV have?
-
Number of ENLV employees currently stands at 34. ENLV operates from 14 Einstein Street, Ness Ziona, TA 7403618, IL.
-
Link for ENLV official website?
-
Official Website of ENLV is: https://www.enlivex.com
-
How do I contact ENLV?
-
ENLV could be contacted at phone #972 8 662 3301 and can also be accessed through its website. ENLV operates from 14 Einstein Street, Ness Ziona, TA 7403618, IL.
-
How many shares of ENLV are traded daily?
-
The average number of ENLV shares traded daily for last 3 months was 31.57K.
-
What is the market cap of ENLV currently?
-
The market value of ENLV currently stands at $98.3M with its latest stock price at $5.84